If you are shopping for a mortgage, you have probably seen all sorts of offers and advertisements aimed at first-time home buyers and wondered if these are really as good as they sound. In some cases, “first-time” programs are little more than attention getting marketing messages from lenders, while in others they are actual assistance programs for people who may otherwise face challenges with qualifying for a home mortgage or finding a home loan at an affordable interest rate. With this in mind, it is important to understand the difference between mortgage lender marketing programs, actual loan programs, and financial assistance programs.
You can be a first-time home buyer more than once
First of all, even if you have previously owned a home, you (or your spouse) may still qualify as a first-time home buyer. According to the U.S. Department of Housing and Urban Development, first-time home buyer status is not limited to people who have never owned a home before (although that criteria obviously applies). For lending purposes, a first-time home buyer includes anyone who fits one or more of these conditions:
stock report: RenaissanceRe Holdings Ltd.(RNR)
- [By WWW.MONEYSHOW.COM]
RenaissanceRe Holdings (RNR) is a global provider of reinsurance, as well as various types of insurance and related services. The company was founded in 1993 and is headquartered in Bermuda, notes Jack Adamo, editor of Insiders Plus.
stock report: Signet Jewelers Limited(SIG)
- [By Chris Lange]
The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Signet Jewelers Limited (NYSE: SIG), which rose roughly 9% to $52.52. The stocks 52-week range is $46.09 to $101.46. Volume was nearly 5 million on the day compared to the average of 1.8 million.
- [By Ben Levisohn]
Signet Jewelers (SIG) soared to the top of the S&P 500 today after reporting better-than-expected earnings and offering a staunch defense of the company’s culture.
Signet Jewelersgained 8.7% to $70.02 today, while the S&P 500 ticked up 0.1% to 2,364.87.
CFRA’s Efraim Levy still sees “risks” despite Signet’s defense of itself today:
We lower our 12-month target by $4 to $81, or 11X our FY 18 (Jan.) EPS of $7.35 (reduced $0.30). We apply a P/E below SIG’s 10-year forward average of 13.4X, to reflect challenges of negative same-store sales, offset by our favorable longer-term view of SIG’s market position. SIG today addressed recent headlines, but we still see risks, despite implied upside potential to our target. Posts adjusted Jan-Q EPS of $4.03 vs. $3.63, in line with Capital IQ consensus and January guidance. Same-store sales fell an in-line 4.5%, dragged down by the Sterling Jewelers division.
Signet Jewelers’ market capitalization rose to $4.9 billion today from $4.5 billion yesterday.
- [By Peter Graham]
A long term performance chart shows shares of Tiffany & Co heading back towards late 2014 highs while mid capSignet Jewelers Ltd (NYSE: SIG) peaked in late 2015 andhas continued to fall off since then:
stock report: Salesforce.com Inc(CRM)
- [By Chris Lange]
Salesforce.com Inc. (NYSE: CRM) fiscal third-quarter results also are scheduled for Tuesday. The consensus forecast is $0.37 in EPS on $2.65 billion in revenue. Shares were last seen at $107.58. The consensus price target is $115.20. The 52-week range is $66.43 to $107.85.
- [By Sreekanth Anasa]
According to Equities.com analyst Michael Markowski, Microsoft could be the first digital companyhit a $1 trillion market capitalization. As of Thursday, Microsoft had the third largest market cap of $486.83B, behind Apple Inc ($619.79B) and Alphabet Inc ($543.04B).Microsoft’s $26 billion acquisition of LinkedIn is the big ticket according toanalyst Michael Markowski.The LinkedIn acquisition expands its PE and positions Microsoft to capitalize from emerging online crowdsourced funding.Michael Markowski states”It has a monopoly on the business social media niche or community.” It is well positioned to take advantage of tons of data of 467M LinkedIn users.Microsoft also plans to use LinkedIns social graph to bolster its customer relationship management tool to compete with industry-leadersalesforce (NYSE:CRM).
- [By WWW.MONEYSHOW.COM]
Cloud-software leader Salesforce (CRM) – my Top Pick for 2017 among large cap technology stocks — remains well positioned to reap the benefits of the transition away from on-premises solutions.
- [By WWW.THESTREET.COM]
“There are two things that mess up your relationships, it’s anger and fear,” explains Robbins. Robbins points to Salesforce (CRM) CEO Marc Benioff as being a total giver, which has set him up for success in business.
stock report: iShares Nasdaq Biotechnology Index Fund(IBB)
- [By Ben Levisohn]
Biotech stocks are having a great day today–iShares Nasdaq Biotechnology ETF (IBB) has climbed 2.5% to $276.92–leading some to suggest that 2017 could be better for investors than 2016 was. Not Baird’s Brian Skorney and Michael Ulz, who “don’t think 2017 will be worse than 2016″ but “aren’t quite sure it will be much better.” They explain why:
Agence France-Presse/Getty Images
Short story is, growth products are slowing and large net price increases are appearing increasingly unsustainable, even if the government doesn’t intervene. The innovation cycle appears to be in a waning period and, so far, large-caps with boatloads of cash seem to be hesitant to act. 2017 should have some excitement. We may finally see a successful registrational study in Alzheimer’s disease (Axovant Sciences’ (AXON) intepirdine or Merck’s (MRK) verubecestat), CAR T will finally get to plead its case, and we may find out once and for all if those ‘transformational’ PCSK9s are just that…
A steadily building pharma cash war chest is a big offsetting tailwind. As Princess Leia would say, “Help me M&A, you’re my only hope.”
Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).
- [By Craig Jones]
Guy Adami believes that iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is a Buy. He explained that it held well in a tough trading session for the rest of the market.
- [By ]
The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.
stock report: Match Group, Inc.(MTCH)
- [By Jeremy Bowman]
In its first full year as a publicly traded company, online dating conglomerateMatch Group (NASDAQ:MTCH) surged past expectations, climbing 26%.
A number of factors led to its standout performance, including blockbuster growth from Tinder, strong operating leverage, and consistently beaten earnings estimates. Let’s take a closer look at how things played out in 2016.
- [By Peter Graham]
Small cap dating site stock Match Group Inc (NASDAQ: MTCH), which was spun off from media and Internet stock IAC/InterActiveCorp (NASDAQ: IAC) and is a peer or remaining dating stock Spark Networks Inc (NYSEMKT: LOV), is the eight most shorted stock on theNASDAQ with short interest of 43.96% according to Highshortnterest.com.
stock report: Rockwell Medical Technologies Inc.(RMTI)
- [By Lisa Levin]
Thursday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Keryx Biopharmaceuticals (NASDAQ: KERX) and Rockwell Medical Inc (NASDAQ: RMTI).
- [By Alex McGuire]
As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…
Pharmaceutical Stock Current Share Price April 2017 Gain
Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%
The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.